









市場行情
/
股票
/
nasdaq-vrca
/

Verrica Pharmaceuticals Inc

VRCA

7.820USD

-0.290-3.58%

收盤 12/19, 16:00（美東）報價延遲15分鐘

74.21M總市值

虧損本益比TTM



Verrica Pharmaceuticals Inc

7.820

-0.290-3.58%

概覽公司財務分析

概覽

公司

財務

分析

關於 Verrica Pharmaceuticals Inc 公司

Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing and selling medications for skin diseases requiring medical intervention. The Company's product portfolio consists of one approved product with several potential follow-on indications, as well as an additional pipeline product. Its commercial product, YCANTH (VP-102), is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. YCANTH (VP-102) is being developed for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. It is also engaged in developing YCANTH (VP-102) for a potential follow-on indication for the treatment of common warts. Its second development candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma (BCC).

Verrica Pharmaceuticals Inc簡介



公司代碼VRCA

公司名稱Verrica Pharmaceuticals Inc

上市日期Jun 15, 2018

CEORieger (Jayson)

員工數量71

證券類型Ordinary Share

年結日Jun 15

公司地址44 West Gay Street

城市WEST CHESTER

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編19380

電話14844533300

網址https://verrica.com/

公司代碼VRCA

上市日期Jun 15, 2018

CEORieger (Jayson)

Verrica Pharmaceuticals Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Jayson Rieger

President, Chief Executive Officer, Director

183.30K

+105.98%

Mr. David Zawitz

Chief Operating Officer

21.00K

+90.91%

Dr. Noah L. Rosenberg, M.D.

Chief Medical Officer

2.36K

Dr. Diem Nguyen, Ph.D.

Independent Director

10.00

Dr. Gavin Corcoran

Independent Director

2.00

Dr. Lawrence Eichenfield, M.D.

Independent Director

Mr. John J. Kirby

Interim Chief Financial Officer, Interim Principal Financial Officer

Mr. Paul B. Manning

Chairman of the Board

Mr. Mark A. Prygocki, Sr.

Independent Director

名稱

名稱/職務

職務

持股

持股變動

Dr. Jayson Rieger

President, Chief Executive Officer, Director

183.30K

+105.98%

Mr. David Zawitz

Chief Operating Officer

21.00K

+90.91%

Dr. Noah L. Rosenberg, M.D.

Chief Medical Officer

2.36K

Dr. Diem Nguyen, Ph.D.

Independent Director

10.00

Dr. Gavin Corcoran

Independent Director

2.00

Dr. Lawrence Eichenfield, M.D.

Independent Director

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 12月5日週五

持股股東

股東類型

持股股東

佔比

Manning (Paul B.)

28.51%

BKB Growth Investments LLC

20.94%

Caligan Partners, LP

5.78%

Affinity Asset Advisors LLC

4.42%

Armistice Capital LLC

4.00%

其他

36.35%

持股股東

佔比

Manning (Paul B.)

28.51%

BKB Growth Investments LLC

20.94%

Caligan Partners, LP

5.78%

Affinity Asset Advisors LLC

4.42%

Armistice Capital LLC

4.00%

其他

36.35%

股東類型

持股股東

佔比

Individual Investor

31.41%

Corporation

21.10%

Hedge Fund

14.84%

Investment Advisor

2.60%

Investment Advisor/Hedge Fund

2.43%

Venture Capital

0.18%

Research Firm

0.02%

其他

27.43%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

171

2.46M

26.06%

-1.46M

2025Q2

183

8.91M

96.35%

+3.15M

2025Q1

194

69.94M

75.99%

+19.16M

2024Q4

191

70.39M

77.72%

+35.42M

2024Q3

179

29.67M

67.28%

-5.27M

2024Q2

173

33.68M

79.75%

-1.13M

2024Q1

171

34.51M

82.01%

-2.46M

2023Q4

170

35.04M

83.66%

+1.56M

2023Q3

172

32.74M

78.91%

-2.85M

2023Q2

169

31.35M

77.69%

+2.98M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Manning (Paul B.)

4.98M

52.73%

+3.12M

+167.58%

Nov 26, 2024

BKB Growth Investments LLC

597.61K

6.33%

+597.61K

Nov 22, 2024

Caligan Partners, LP

923.91K

9.78%

+24.62K

+2.74%

Jun 30, 2025

Armistice Capital LLC

888.13K

9.4%

+31.39K

+3.66%

Jun 30, 2025

The Vanguard Group, Inc.

216.83K

2.3%

-19.30K

-8.17%

Jun 30, 2025

Stalfort (John A)

187.38K

1.98%

+23.81K

+14.56%

Apr 01, 2025

Rieger (Jayson)

88.99K

0.94%

+30.02K

+50.90%

Apr 01, 2025

Sovran Advisors LLC

75.04K

0.79%

+35.82K

+91.35%

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

iShares Micro-Cap ETF

iShares Russell 2000 Growth ETF

Goldman Sachs ActiveBeta US Small Cap Equity ETF

Dimensional US Core Equity 1 ETF

Global X Russell 2000 Covered Call ETF

Invesco Dorsey Wright SmallCap Momentum ETF

Avantis US Small Cap Equity ETF

ProShares UltraPro Russell2000

Global X Russell 2000 ETF

iShares Russell 2000 ETF

iShares Micro-Cap ETF

佔比0%

iShares Russell 2000 Growth ETF

佔比0%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

佔比0%

Dimensional US Core Equity 1 ETF

佔比0%

Global X Russell 2000 Covered Call ETF

佔比0%

Invesco Dorsey Wright SmallCap Momentum ETF

佔比0%

Avantis US Small Cap Equity ETF

佔比0%

ProShares UltraPro Russell2000

佔比0%

Global X Russell 2000 ETF

佔比0%

iShares Russell 2000 ETF

佔比0%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

Jul 23, 2025

Merger

10→1

公告日期

類型

比率

Jul 23, 2025

Merger

10→1

常見問題

Verrica Pharmaceuticals Inc的前五大股東是誰？



Verrica Pharmaceuticals Inc的前五大股東如下：
Manning (Paul B.)
持有股份：4.98M
佔總股份比例：52.73%。
BKB Growth Investments LLC
持有股份：597.61K
佔總股份比例：6.33%。
Caligan Partners, LP
持有股份：923.91K
佔總股份比例：9.78%。
Armistice Capital LLC
持有股份：888.13K
佔總股份比例：9.40%。
The Vanguard Group, Inc.
持有股份：216.83K
佔總股份比例：2.30%。